135 / 164
ESTRO CONFERENCES
135
FRIDAY 5 MAY 2017
Course directors:
J. Alsner (DK) and M-C. Vozenin (CH)
COURSE AIM
Enable participants to understand the scientific and
clinical aspects associated with discovery, exploration,
and validation of biomarkers for personalised/precision
radiation oncology (PRO) and raise awareness of key
challenges in this important field.
LEARNINGOBJECTIVES
• To comprehend the basic principles of prognostic and
predictive biomarkers
• To assess the relevance of biomarkers for normal
tissue toxicity
• To assess the relevance of biomarkers for tumour
response
• To propose strategies for validation of biomarkers
• To propose strategies for implementing imaging and
molecular biomarkers for PRO
• To analyse legal and patent aspects for the clinical
use of biomarkers.
WHO SHOULD ATTEND?
• Radiation oncologists, particularly those in the early
stage of their career, who are keen to understand how
biomarkers are important for PRO
• Radiation biologists seeking information on how
to maximise the clinical impact of their scientific
discoveries
• Medical physicists and RTTs looking for an overview
and update of recent and ongoing developments in
the field of biomarkers.
CONTENT
Prognostic and predictive biomarkers
Tumour response
• Genetic biomarkers: mutations andmRNA / miRNA
profiles
• Imaging biomarkers: PET / MR
• Imaging biomarkers: radiomics
• Circulating tumour cells and cell-free DNA / RNA.
Normal tissue
• Genetic biomarkers: genomic DNA
• Genetic biomarkers: mitochondrial DNA
• Proteomic / metabolomic biomarkers
• Functional biomarkers.
Validation
• Design methodology for biomarker based radio-
therapy trials
• Clinical trial example (EORTC-1219): Randomised
prospectivemulticenter study testing a radiosensitizer
and a predictive biomarker.
RADIOBIOLOGY PRE-MEETING COURSE
Clinical application of biomarkers: How to discover, explore, and validate biomarkers for
normal tissue toxicity and tumour response